Introduction: Lupus anticoagulant (LA) is commonly present in patients with systemic lupus erythematosus (SLE) who present with an ischemic cerebral stroke. Reports have noted the presence of LA in patients with epilepsy who do not have SLE. These patients are usually elderly, and it has been postulated that their epilepsy is due to subclinical ischemic infarcts.
INTRODUCTION
Lupus anticoagulant (LA) and anticardiolipin antibodies (ACA) are antiphospholipid antibodies (APLA). APLA are associated with thrombosis, fetal loss and thrombocytopenia in systemic lupus erythematosus (SLE). There are anecdotal reports of the association of APLA in patients with myelopathy, Guillain-Barré syndrome, migraine, chorea, optic neuritis, myasthenia gravis and epileptic seizures 1 . The recognition of these immunoglobulin fractions in association with neurological diseases could impact the manner in which each individual syndrome is treated.
APLA occur in high prevalence in patients with SLE. Currently, the pathogenesis of epilepsy in SLE is unclear. Seizures can occur as a result of ischemic vascular infarcts; however, it is possible that antibody fractions bind to the cerebral cortex by an immunemediated mechanism which predisposes the patient to develop seizures. In the past, studies have attempted to correlate the presence of APLA fractions and an increased incidence of epileptic seizures 2, 3 . This paper describes two young patients with epilepsy who did not fulfill the criteria for SLE who were found to have LA present in their sera.
CASE REPORTS Case 1
A 28-year-old, right-handed woman with no significant past medical history presented with her first seizure. Two days prior to presentation she had a sudden onset of a severe occipital headache and blurred vision. These symptoms resolved spontaneously after ten minutes. Later that evening she had a generalized tonic-clonic seizure that lasted about 2 minutes. In the emergency department she denied recent fever, chills, nausea or vomiting. There was no history of abuse of alcohol, drugs or tobacco. She was not taking any medications. Her past medical history was significant for sickle cell trait, a cholecystectomy several years previously and two miscarriages. Her family history was significant for a mother who had SLE and several cousins with seizures. A rheumatological consultant noted that she did not have the clinical features of SLE. Physical examination was significant for an II/VI diastolic cardiac ejection murmur. Her neurological examination was normal. Serological tests revealed a prolonged activated partial thromboplastin time (aPTT) of 48 seconds and LA was positive. An electroencephalogram (EEG) revealed recurrent left temporal spike discharges. Magnetic resonance imaging (MRI) and MR angiography (MRA) of the brain showed an area of hyperintensity in the left posterior parietal and periventricular white matter. No cortical lesions or other abnormalities were noted.
Case 2
A 34-year-old man presented for evaluation of medically refractory seizures. He denied the use of alcohol, drugs, or tobacco. His past medical history was significant for a motor vehicle accident 10 years prior to his seizure onset, subsequent partial paraparesis and bilateral deep vein thromboses. Medications on presentation were carbamazepine and warfarin. His family history was noncontributory. General physical and neurological examinations were remarkable for bilateral lower extremity atrophy and weakness (4/5). His serological tests revealed a prolonged aPTT of 48 seconds and LA was positive. An EEG revealed bitemporal sharp waves whereas a brain MRI showed two small areas of hyperintensity in the left deep frontal white matter.
DISCUSSION
Two young patients with epileptic seizures who were LA positive and did not have SLE or cerebral cortical infarcts are presented. Previous case reports of epilepsy and LA without SLE have been of older patients (50-75 years old) with some showing brain atrophy or gray matter cerebral infarction. In this paper LA-positive patients with seizures were significantly younger and only had minimal white matter abnormalities. This suggested an etiology independent of arterial infarction associated with strokes as the causative mechanism for epilepsy in these cases. Therefore, the presence of LA in young adults without SLE may be associated with an increased susceptibility to develop epileptic seizures by a yet poorly understood antibody-mediated immunologic mechanism.
Approximately 10% of all patients with SLE develop epileptic seizures at some stage of their disease 2 , which is almost ten times greater than that of the general population. Between 5-10% of those patients have onset of seizures several years before clinical onset of SLE 4 . For years it was thought that seizures in SLE were a result of thrombosis of cortical blood vessels induced by the procoagulant effects of APLA. The resulting cortical infarction would be more prone to pathological epileptic activity 5 .
LA, an APLA fraction, despite inducing a prothrombotic state, prolongs coagulation by interacting with phospholipid-dependent mechanisms. LA inhibits prothrombinase (a complex of factors Xa, Va, phospholipid, and calcium), thereby blocking the activation of prothrombin by the complex. Paradoxically, the characteristic serological abnormalities are a prolonged aPTT and PT even though a procoagulant state is present in the serum 6 . The precise mechanism by which LA induces a prothrombotic state is poorly understood, but presumed mechanisms include dysfunction of endothelial cells, platelets, and coagulation proteins 7, 8 .
In the present cases, it was initially believed that seizures were due to a vascular insult in the gray matter that made the tissue epileptogenic. However, the neurological examination and neuroimaging did not suggest cortical involvement in either case. Also, these patients did not fulfill the American Rheumatism Association criteria for SLE 9 . This suggested other neuropathological mechanisms might be responsible for the etiology of the seizures in these patients.
Immune system mechanisms play an important role in some forms of epilepsy. In patients with Rasmussen's encephalitis (RE), a particularly severe form of epilepsy, patients gradually develop refractory continuous partial seizures or epilepsia partialis continua through an immune complement mechanism mediated by glutamate receptor 3 (GluR3) autoantibodies to cortical neurons 10, 11 . Removal of antibodies through plasma exchange has been demonstrated to reduce the seizure frequency and improve neurologic function transiently 10 . Similarly, it has been suggested that epilepsy in patients with SLE may be a secondary result of an immune-mediated mechanism by APLA, independent of thrombotic infarcts as has been previously hypothesized 2, 3 . Chapman et al. 12 demonstrated that IgG from patients with high levels of APLA depolarized synaptosomes from rodent brainstem. The depolarization of neurons by APLA could theoretically lower the seizure threshold, thereby predisposing the tissue to epileptogenesis.
While the present case series included only two patients who were LA positive without SLE and had seizures, previous clinical reports have noted an association between the presence of APLA and increased epileptic seizure prevalence. Inzelberg and Korczyn 3 described four patients with late-onset seizures (age > 54 years old) who had LA-positive sera but not clinical SLE and minimal brain MRI changes. Other retrospective case reports have correlated an increased seizure frequency in patients with SLE who also had APLA in their sera. In 21 unselected patients with seizures of unclear etiology, epilepsy was statistically significantly associated with the presence of ACA and/or LA fractions in comparison to controls 2 . In another study of patients with SLE, epilepsy was 3.7 times more frequent in patients who had ACA than in those who did not have ACA 13 . In a series of 23 children with cryptogenic epileptic seizures without serological evidence of SLE or MRI evidence of focal ischemic infarcts, three had frontal lobe seizures and APLA present in their sera 14 .
Currently, there are few data to suggest that immune-mediated mechanisms are intimately involved in the pathophysiology of any epilepsy other than RE. However, case reports suggest that the presence of ACLA, like LA, may make a patient more susceptible to the future development or exacerbation of underlying epileptic seizures. This, in turn, may create alternative therapies for patients with these types of seizures.
